Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition

Oncotarget

Volumn 7, Issue 9, 2016, Pages 10522-10535

  Raja, Srikumar M ^a,e   Desale, Swapnil S ^b   Mohapatra, Bhopal ^a   Luan, Haitao ^a   Soni, Kruti ^b   Zhang, Jinjin ^b   Storck, Matthew A ^a   Feng, Dan ^a   Bielecki, Timothy A ^a   Band, Vimla ^c   Cohen, Samuel M ^c   Bronich, Tatiana K ^b   Band, Hamid ^a,b,c,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d Biochemistry and Molecular Biology College of Medicine 985950 Nebraska Medical Center   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; ErbB2; HSP90; Targeted drug delivery; Trastuzumab

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; NANOGEL; NANOPARTICLE; TANESPIMYCIN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL SPECIFICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOCYTOSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYSOSOME; MOLECULARLY TARGETED THERAPY; MOUSE; NANOMEDICINE; NONHUMAN; ONCOGENE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UBIQUITINATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; FEMALE; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MICE; MICE, NUDE; NANOPARTICLES; RECEPTOR, ERBB-2; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961642239     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7231     Document Type: Article

References (85)

1. Mehra NK, Mishra V and Jain NK. Receptor-based targeting of therapeutics. Ther Deliv. 2013; 4:369-394
2. Mathew J and Perez EA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol. 2011; 23:594-600
3. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS and Blättler WA. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006; 66:4426-4433
4. Ritchie M, Tchistiakova L and Scott N. (2013). Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs: Taylor & Francis, pp. 13-21
5. Sutherland MSK, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF and Doronina SO. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptidelinked anti-CD30-auristatin conjugates. J Biol Chem. 2006; 281:10540-10547
6. Le Roy C and Wrana JL. Clathrin-and non-clathrinmediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005; 6:112-126
7. Gonnord P, Blouin CM and Lamaze C. (2012). Membrane trafficking and signaling: two sides of the same coin. Seminars in cell & developmental biology: Elsevier, pp. 154-164
8. Chung BM, Tom E, Zutshi N, Bielecki TA, Band V and Band H. Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. World J Clin Oncol. 2014; 5:806
9. Molfetta R, Quatrini L, Gasparrini F, Zitti B, Santoni A and Paolini R. Regulation of Fc receptor endocytic trafficking by ubiquitination. Front Immunol. 2014; 5
10. Piper RC and Lehner PJ. Endosomal transport via ubiquitination. Trends Cell Biol. 2011; 21:647-655
11. Sorkin A and Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2009; 315:683-696
12. Marmor MD and Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene. 2004; 23:2057-2070
13. Wright MH, Berlin I and Nash PD. Regulation of endocytic sorting by ESCRT-DUB-mediated deubiquitination. Cell Biochem Biophys. 2011; 60:39-46
14. Tu C, Ahmad G, Mohapatra B, Bhattacharyya S, Ortega-Cava C, Chung BM, Wagner K-U, Raja SM, Naramura M and Band V. ESCRT proteins: Double-edged regulators of cellular signaling. Bioarchitecture. 2011; 1:45-48
15. Raiborg C and Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature. 2009; 458:445-452
16. Wandinger-Ness A and Zerial M. Rab proteins and the compartmentalization of the endosomal system. Cold Spring Harb Perspect Biol. 2014:a022616
17. Aloisi AL and Bucci C. Rab GTPases-cargo direct interactions: fine modulators of intracellular trafficking. Histol Histopathol. 2013; 28:839-849
18. Mellman I and Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol. 2013; 5:a016949
19. Casi G and Neri D. Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release. 2012; 161:422-428
20. Kim EG and Kim KM. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomolecules & therapeutics. 2015; 23:493
21. Panowski S, Bhakta S, Raab H, Polakis P and Junutula JR. (2014). Site-specific antibody drug conjugates for cancer therapy. MAbs: Taylor & Francis, pp. 34-45
22. Murthy N, Xu M, Schuck S, Kunisawa J, Shastri N and Fréchet JM. A macromolecular delivery vehicle for proteinbased vaccines: acid-degradable protein-loaded microgels. Proc Natl Acad Sci U S A. 2003; 100:4995-5000
23. Hendriks BS, Klinz SG, Reynolds JG, Espelin CW, Gaddy DF and Wickham TJ. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicinmediated drug delivery: multiple low-affinity interactions lead to a threshold effect. Mol Cancer Ther. 2013; 12:1816-1828
24. Yousefpour P, Atyabi F, Farahani EV, Sakhtianchi R and Dinarvand R. Polyanionic carbohydrate doxorubicindextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations. Int J Nanomedicine. 2011; 6:1487-1496
25. Inoue S, Ding H, Portilla-Arias J, Hu J, Konda B, Fujita M, Espinoza A, Suhane S, Riley M and Gates M. Polymalic Acid-Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by Inhibiting both HER2/neu Receptor Synthesis and Activity. Cancer Res. 2011; 71:1454-1464
26. Miyano T, Wijagkanalan W, Kawakami S, Yamashita F and Hashida M. Anionic Amino Acid Dendrimer-Trastuzumab Conjugates for Specific Internalization in HER2-Positive Cancer Cells. Mol Pharm. 2010; 7:1318-1327
27. Baulida J, Kraus MH, Alimandi M, Di Fiore PP and Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem. 1996; 271:5251-5257
28. Meijer IM, van Rotterdam W, van Zoelen EJ and van Leeuwen JE. Recycling of EGFR and ErbB2 is associated with impaired Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH. Cell Signal. 2012; 24:1981-1988
29. Wang Z, Zhang L, Yeung TK and Chen X. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell. 1999; 10:1621-1636
30. Mosesson Y, Mills GB and Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer. 2008; 8:835-850
31. Bailey TA, Luan H, Tom E, Bielecki TA, Mohapatra B, Ahmad G, George M, Kelly DL, Natarajan A and Raja SM. A kinase inhibitor screen reveals protein kinase c-dependent endocytic recycling of erbb2 in breast cancer cells. J Biol Chem. 2014; 289:30443-30458
32. Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, Ortega-Cava C, Lakku-Reddi A, Naramura M and Band V. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathwaydependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther. 2008; 7:1630-1640
33. Austin CD, De Mazière AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J and Scheller RH. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004; 15:5268-5282
34. Marx C, Held JM, Gibson BW and Benz CC. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res. 2010; 70:3709-3717
35. Cortese K, Howes MT, Lundmark R, Tagliatti E, Bagnato P, Petrelli A, Bono M, McMahon HT, Parton RG and Tacchetti C. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments. Mol Biol Cell. 2013; 24:129-144
36. Lerdrup M, Hommelgaard AM, Grandal M and van Deurs B. Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J Cell Sci. 2006; 119:85-95
37. Kim JO, Kabanov AV and Bronich TK. Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin. J Control Release. 2009; 138:197-204
38. Kim JO, Nukolova NV, Oberoi HS, Kabanov AV and Bronich TK. Block ionomer complex micelles with crosslinked cores for drug delivery. Polym Sci Ser A Chem Phys. 2009; 51:708-718
39. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, DiPetrillo TA, Wazer DE, Band V and Band H. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem. 2003; 278:13829-13837
40. Baselga J, Albanell J, Molina MA and Arribas J. (2001). Mechanism of action of trastuzumab and scientific update. Seminars in oncology: Elsevier, pp. 4-11
41. Albanell J, Codony J, Rovira A, Mellado B and Gascón P. (2003). Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. New Trends in Cancer for the 21st Century: Springer, pp. 253-268
42. Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FK and Gewirtz DA. Growth arrest and nonapoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol. 1996; 51:931-940
43. Konopa J. G 2 block induced by DNA crosslinking agents and its possible consequences. Biochem Pharmacol. 1988; 37:2303-2309
44. Young RC, Ozols RF and Myers CE. The anthracycline antineoplastic drugs. N Engl J Med. 1981; 305(3):139-153
45. Sahay G, Alakhova DY and Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010; 145:182-195
46. Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, Karagiannis E, Love K, Chen D and Zoncu R. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nature Biotechnol. 2013; 31:653-658
47. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H and Akslen LA. Molecular portraits of human breast tumours. Nature. 2000; 406:747-752
48. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen M, Van de Rijn M and Jeffrey S. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98:10869-10874
49. Roepstorff K, Grøvdal L, Grandal M, Lerdrup M and van Deurs B. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol. 2008; 129:563-578
50. Phillips GDL, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV and Lutz RJ. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68:9280-9290
51. Xu W, Mimnaugh EG, Kim J-S, Trepel JB and Neckers LM. Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2. Cell Stress Chaperones. 2002; 7:91
52. Citri A, Kochupurakkal BS and Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle. 2004; 3:50-59
53. LoRusso PM, Weiss D, Guardino E, Girish S and Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011; 17:6437-6447
54. Arteaga CL. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer? Clin Cancer Res. 2011; 17:4919-4921
55. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME and Sugarman S. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011; 17:5132-5139
56. Johnson ML, Helena AY, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG and Riely GJ. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J Clin Oncol. 2015:JCO. 2014.2059. 7328
57. Spreafico A, Delord J, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard P, Akimov M, Lu H and Pain S. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer. 2015
58. Modi S, Saura C, Henderson C, Lin NU, Mahtani R, Goddard J, Rodenas E, Hudis C, O'Shaughnessy J and Baselga J. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Res Treat. 2013; 139:107-113
59. Pacey S, Banerj U, Judson I and Workman P. (2006). Hsp90 inhibitors in the clinic. Molecular Chaperones in Health and Disease: Springer, pp. 331-358
60. Infante JR, Weiss GJ, Jones S, Tibes R, Bauer TM, Bendell JC, Hinson JM, Von Hoff DD, Burris HA and Orlemans EO. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. Eur J Cancer. 2014; 50:2897-2904
61. Saif MW, Takimoto C, Mita M, Banerji U, Lamanna N, Castro J, O'Brien S, Stogard C and Von Hoff D. A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Clin Cancer Res. 2014; 20:445-455
62. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL and Erlichman C. A phase I trial of twice-weekly 17-allylaminodemethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res. 2006; 12:6087-6093
63. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W and Ivy SP. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2008; 14:7940-7946
64. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J and Ross RW. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011; 78:626-630
65. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S and Avsar E. The HSP90 inhibitor NVP-AUY922 potently inhibits nonsmall cell lung cancer growth. Mol Cancer Ther. 2013; 12:890-900
66. Shimamura T, Lowell AM, Engelman JA and Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 2005; 65:6401-6408
67. Yang J, Mani SA and Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res. 2006; 66:4549-4552
68. Chung BM, Raja SM, Clubb RJ, Tu C, George M, Band V and Band H. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC Cell Biol. 2009; 10:84
69. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B and Poulsen HS. EGFRvIII escapes downregulation due to impaired internalization and sorting to lysosomes. Carcinogenesis. 2007; 28:1408-1417
70. Liu H, Lu J, Hua Y, Zhang P, Liang Z, Ruan L, Lian C, Shi H, Chen K and Tu Z. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. Cell Death Dis. 2015; 6:e1595
71. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C and Agus DB. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002; 8:986-993
72. Tikhomirov O and Carpenter G. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation. J Biol Chem. 2000; 275:26625-26631
73. Gianni L, Salvatorelli E and Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol. 2007; 7:67-71
74. Feldman AM, Lorell BH and Reis SE. Trastuzumab in the Treatment of Metastatic Breast Cancer Anticancer Therapy Versus Cardiotoxicity. Circulation. 2000; 102:272-274
75. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ and Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20:1215-1221
76. van de Donk NW and Dhimolea E. (2012). Brentuximab vedotin. MAbs: Taylor & Francis, pp. 458-465
77. Muta H and Podack ER. CD30: from basic research to cancer therapy. Immunol Res. 2013; 57:151-158
78. Sakisaka T, Meerlo T, Matteson J, Plutner H and Balch WE. Rab-aGDI activity is regulated by a Hsp90 chaperone complex. EMBO J. 2002; 21:6125-6135
79. Chen CY, Sakisaka T and Balch WE. Use of Hsp90 Inhibitors to Disrupt GDI-Dependent Rab Recycling. Methods Enzymol. 2005; 403:339-347
80. George M, Ying G, Rainey MA, Solomon A, Parikh PT, Gao Q, Band V and Band H. Shared as well as distinct roles of EHD proteins revealed by biochemical and functional comparisons in mammalian cells and C. elegans. BMC Cell Biol. 2007; 8:3
81. Naslavsky N and Caplan S. EHD proteins: key conductors of endocytic transport. Trends Cell Biol. 2011; 21:122-131
82. Sandilands E and Frame MC. Endosomal trafficking of Src tyrosine kinase. Trends Cell Biol. 2008; 18:322-329
83. Reiter E and Lefkowitz RJ. GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab. 2006; 17:159-165
84. Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, Zhao X, Reddi AL, Nyong AM and Natarajan A. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther. 2011; 11:263-276
85. Band V, Zajchowski D, Swisshelm K, Trask D, Kulesa V, Cohen C, Connolly J and Sager R. Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res. 1990; 50:7351-7357